Gene Silencing/Gene Editing | Gene News GenomeWeb

Gene Silencing/Gene Editing

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

For several reasons, scientists, as well as gene editing therapy company Editas, think that the first clinical trials for CRISPR-based cures will be for hereditary eye diseases.

The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.

The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.

The pharmaceutical giant is aggressively incorporating the gene manipulating tech, especially in target validation and improving disease models.

Hybrid promoter and recombinant vector comprising the same
Switchable gRNAs comprising apatamers
Methods and compositions for selecting siRNA of improved functionality
miRNA fingerprint in the diagnosis of diseases
Methods for identifying a target site of a Cas9 nuclease
Compositions and methods for inhibiting expression of the ALAS1 gene

Editas Files for IPO

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.